The trials are focused on different targets and indications: CD7+ leukemia/lymphomas in adults (NCT02742727), CD33+ myeloid malignancies in children and adults (NCT02944162), refractory CD19+ malignancies in children and adults as bridge to HSCT transplant (NCT02892695), and MUC1+ solid tumors including malignant glioma of brain, colorectal carcinoma, gastric carcinoma, hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), pancreatic carcinoma, and triple-negative basal-like breast carcinoma (NCT02839954). Here, MUC1 is linked to non-small cell lung carcinoma.